Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection

 Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection

Roche Reports Positive Results of Xofluza (baloxavir marboxil) in Two P-III MINISTONE-2 and BLOCKSTONE Studies for Influenza Infection

Shots:

  • The P-III MINISTONE-2 involves assessing of Xofluza vs oseltamivir in children with influenza infection & showing influenza symptoms aged 1 to <12yrs., resulted in meeting its 1EPs i.e, patients with AEs up to day 29 (46.1% vs 53.4%) and reduction in length of time that the flu virus continued to be released from the body by >2days (24.2 vs 75.8 hrs.)
  • The P-III BLOCKSTONE study involves assessing of Xofluza vs PBO in adults & children with influenza infection confirmed by a rapid influenza diagnostic test. The results demonstrated 86% reduction in developing flu after exposure to an infected person (1.9% vs 13.6%), when fewer criteria for flu were applied showed 76% reduction in developing flu (5.3% vs 22.4%)
  • Xofluza is a one-dose, oral therapy demonstrating efficacy in a wide range of influenza viruses including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies and is an approved therapy in the US for acute influenza in patients aged ≥12yrs.

Source 1, Source 2 to­ read full press release/ article | Ref: Roche, Roche | Image: Canvas Pantone

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post